RxDoctor Payments Data

Blake Moore, MD

Urology · Richmond, VANPI 1992903769

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,250 of the $42,047 with a category attached, or 76.7%. Medical Device Business Services, Inc. accounts for 76.7% of it on its own, with 41 other manufacturers making up the rest. 2025 is the largest year on record at $33,559, 6.6 times the $5,071 reported in 2019. Among urology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$42,047in general payments, 2019–2025

Across 260 payments — averaging $161.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$32K
  • Intuitive Surgical$4K
  • Johnson & Johnson$745
  • Conmed Corporation$636
  • Bayer$578
  • AbbVie$399
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$32,25077%
  • Travel & lodging$1,6174%
  • Food & beverage$5,11612%
  • Education$3,0647%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,047 in reported general payments places this provider in the 90th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$367,778
Medicare patients
1,028
Services billed
18,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron32$24,380
Tamsulosin Hcl804$11,208
GemtesaVibegron18$8,054
Finasteride309$3,404
Tadalafil13$1,851
Trimethoprim32$1,300
Oxybutynin Chloride ErOxybutynin Chloride46$1,175
Doxycycline Monohydrate38$1,102
Silodosin15$982
Dutasteride28$711
Bethanechol Chloride12$582
CefuroximeCefuroxime Axetil46$540
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip16$396
Cefdinir34$303
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim65$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$176$24,38032 claims
Sumitomo Pharma America, Inc.Gemtesa$306$8,05418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →